University of Massachusetts Medical School

University of Massachusetts Medical School
Established	1962
Type	Public
Chancellor	Michael Collins
President	Robert L. Caret
Students	Medicine: 487 Biomedical Sciences: 637 Nursing: 166 (2010)
Location	Worcester, Massachusetts, U.S.A. 42.276815°N 71.762445°W / 42.276815; -71.762445
Campus	Urban
Colors	Blue     , White     , and Black
Website	www.umassmed.edu/

The University of Massachusetts Medical School (UMMS) is one of five campuses of the University of Massachusetts (UMass) system and is home to three schools: the School of Medicine, the Graduate School of Biomedical Sciences, the Graduate School of Nursing; a biomedical research enterprise; and a range of public service initiatives throughout the state. One of the fastest-growing academic health centers in the country, UMMS is located in Worcester, Mass., while the other UMass sites are located in Amherst, Boston, Dartmouth and Lowell. UMMS can alternately be referred to as UMass Worcester.

UMMS is ranked eighth in primary care education and ranked 53rd in research among the nation’s 125 medical schools in the 2011 U.S. News & World Report annual guide, “America’s Best Graduate Schools”. UMMS is also a major center for research. In the past four decades, UMMS researchers have made advances in a broad range of disease families, from HIV and infectious diseases, to cancer and genetic disorders, to diabetes and immune disease. UMMS faculty discovered the link between the immune system and type 1 diabetes, found the genetic cause that underlies the third most common form of the muscular dystrophies, established the fundamental difference between HIV and other retroviruses and co-discovered RNA interference (RNAi), a naturally occurring gene-silencing process that has become a vital tool in research focused on such areas as diabetes, HIV/AIDS and cancer. Currently, UMMS scientists are making strides in collaborative efforts to develop vaccines for the avian flu, HIV and West Nile virus and rabies.

History

UMMS was established by an act of the Massachusetts Legislature in 1962 to provide residents of the Commonwealth an opportunity to study medicine at an affordable cost and to increase the number of primary care physicians practicing in the Commonwealth’s underserved areas.

The School of Medicine accepted its first class of 16 students in 1970. Six years later, a 371-bed hospital opened on campus, and today, the UMMS campus is home to three schools: the School of Medicine and the Graduate School of Biomedical Sciences, opened in 1979, and the Graduate School of Nursing, opened in 1986.

Worcester Foundation for Biomedical Research

Main article: Worcester Foundation for Biomedical Research

The research mission at UMMS was boosted in 1997 with the acquisition of the financially ailing Worcester Foundation for Biomedical Research, the Shrewsbury, Massachusetts institution where researchers developed the combined oral contraceptive pill in the early 1960s.

In 1998, the UMMS system of hospitals and clinics merged with Memorial Health Care to form UMass Memorial Health Care, the largest health care provider in Central Massachusetts and the clinical partner of UMMS.

Academics

School of Medicine

The School of Medicine accepted its first class in 1970. Accredited by the Liaison Committee on Medical Education, the school grants the MD degree to its graduates. With the exception of MD/PhD students, matriculants are required to be Massachusetts residents. Approximately 125 students enroll annually, and more than 2,700 students have received medical degrees from UMMS. The School of Medicine has garnered a national reputation for its primary care program and consistently ranks in the top ten percent in the annual U.S.News & World Report guide, "America’s Best Graduate Schools". Well more than half of each graduating class enters into primary care residencies, a trend that underscores the school’s founding mission. In addition, a high number of graduates practice throughout the state.

Through educational planning, development, innovation and resources, students learn the core knowledge, skills, attitudes and values that serve as the foundation for physician training at UMMS, according to the School of Medicine Web Site SOM Web site. The institution attributes its success in training primary care physicians in part to a curriculum that emphasizes early exposure to community practice, beginning in the first year of medical school. Third-year students are required to complete an innovative clerkship rotation program in which they spend six weeks at a time with community-based physicians. The curriculum's learning objectives are targeted at developing the foundational competencies required of all physicians today, including competency in communication, scientific, and patient and community advocacy skills.

Reflective of the success of these learning objectives are the results of the annual Match Day at UMMS, when students discover where they will begin their careers as doctors. In 2010, National Resident Matching Program results showed that members of the UMMS class were accepted into some of the most competitive residency programs in the country, with 71 percent of graduates entering primary care including obstetrics & gynecology and pediatrics.

Graduate School of Biomedical Sciences

A faculty-initiated PhD program, the Graduate School of Biomedical Sciences (GSBS) trains scientists in a specialty area with a broad background in the basic medical sciences in preparation for conducting research with direct relevance to human disease. According to the GSBS Web site, the GSBS offers students a multidisciplinary program of study in which they have freedom of choice in curriculum and in the selection of mentors for their graduate thesis research—an approach that is matched by very few graduate programs in the nation.

Since the first class of seven students enrolled in 1979, more than 300 students have earned PhDs from the GSBS. The program, which continues to grow and evolve as new frontiers in science are discovered and explored, is gaining national and international recognition for excellence.

Graduate School of Nursing

Since the opening of the Graduate School of Nursing (GSN) in 1986, more than 600 students have obtained a nursing master’s, post-master’s or doctoral degree from the school. The GSN prepares professional and advanced practice nurses, nurse scientists and educators as leaders in nursing and health care delivery to diverse populations through education, research, practice and service, according to the GSN Web site. The theoretical foundations of nursing, research process and design, societal influences on nursing, advanced pathophysiology, pharmacology, health assessment and specialty content are the basis of study at the GSN. Advanced practice nurses receive professional education and training to become adult acute/critical care nurse practitioners, adult ambulatory/community care nurse practitioners and advanced practice nurse educators. The GSN also offers subspecialty professional education and training in selected areas.

Research

Over the past decade, UMMS has emerged on the national scene as a major center for research. In 1998, UMMS researcher Craig Mello, an investigator of the prestigious Howard Hughes Medical Institute, and his colleague Andrew Fire, then of the Carnegie Institution of Washington, discovered RNA interference (RNAi). Mello and Fire demonstrated that small pieces of double-stranded RNA had interfered with the expression of a gene whose coding sequence of DNA was similar to that of the RNA they tested. Since the discovery of RNAi, researchers at UMMS and around the world have taken advantage of its technology to speed investigation into a variety of diseases. Craig C. Mello, PhD, and his colleague Andrew Fire, PhD, of Stanford University, received the 2006 Nobel Prize in Physiology or Medicine for their discoveries related to RNA interference.

UMMS scientists also pioneered the fundamental elements of DNA-based flu vaccines in the 1990s. Today, UMMS Professor of Medicine Shan Lu, leader of the UMMS DNA vaccine efforts, and his colleagues have partnered with PowerMed, a British immunotherapeutics company, to advance the development of a potential avian flu vaccine. Lu’s team has also been recognized for its work in the creation of an HIV vaccine, which, in Phase I testing, was found to generate antibody and T-cell responses in otherwise healthy people not infected with HIV.

The institution’s strong commitment to its research mission is reflected in its ranking of second among 10 public medical schools in the Northeast in the amount of funds awarded by the National Institutes of Health. Federal and private research grants and contracts at UMMS rose from about $2 million in 1977 to more than $255 million in 2010, putting UMMS in the top third of all research medical schools, public or private. UMMS currently supports more than 260 investigators working on advancements in the treatment of disease and injury.

The UMMS portfolio of commercial ventures and intellectual property continues to reap great dividends for the institution and the University of Massachusetts system. Catapulted by the success of UMMS licenses and patents, including high profile intellectual property related to RNAi gene-silencing technology and drug and vaccine development, UMass ranked eighth in the nation in generating income from the licensing of faculty-derived discoveries and products and generated $70,553,428 in technology transfer income in FY 2009, executing 50 technology licenses and options and creating one startup company according to the Fiscal Year 2009 report released by the Association of University Technology Managers.

Grants

The UMass Medical School has strategic affiliations with various healthcare organizations and research programs. Its largest publicly funded affiliate in the field of cancer research is the Quality Assurance Review Center (QARC). Located off campus in Lincoln, Rhode Island, thousands of radiotherapy (RT) reviews per year are conducted at QARC according to various governmental and pharmaceutical protocols. Supported by the National Cancer Institute (NCI) and the National Institutes of Health (NIH), QARC receives radiotherapy data from around one-thousand hospitals in both the United States and abroad. Over forty-thousand cases have been reviewed at QARC since its official inception in 1980.

Massachusetts Biologic Laboratories

The University of Massachusetts Biologic Laboratories (commonly referred to as MBL) is the only publicly owned, non-profit FDA-licensed manufacturer of vaccine and other biologic products in the United States. Established in 1894 by the state Board of Health to produce diphtheria antitoxin, the operations of the MBL were conducted under the auspices of the Commonwealth of Massachusetts, Department of Public Health until 1997. The University of Massachusetts Biologic Laboratory was re-established by the Massachusetts legislature to operate with an executive director and an advisory board constituted with membership representing senior leaders from the Department of Public Health, the University of Massachusetts medical programs, as well as additional members appointed by the President of University of Massachusetts Board of Trustees. Although operating independently on its Jamaica Plain and Mattapan campuses in south Boston, MBL is administered under the umbrella of the University of Massachusetts Medical School. MBL remains committed to its mission of discovery, development, and production of vaccine and biologic medicines, and the clinical research underpinning their use.

Over the years, the MBL has introduced into general use vaccines to prevent pertussis, tetanus, diphtheria, and other diseases. The lab’s scientists have also pioneered plasma products to protect infants and toddlers from serious infectious diseases. In recent years, the MBL has been called upon to respond to the threat of such emerging public health issues as SARS, avian flu and rabies. During the past two decades, the MBL has also been an active participant in the national effort to develop and produce “orphan products,” which are those drugs intended for limited populations (less than 200,000 patients per year). Many of these are critical, life-saving products for those affected by a rare disease. Despite their importance, commercial manufacturers are often reluctant to invest the resources required to bring these products to market. The MBL, however, has developed or collaborated on five such products in the past 20 years. To continue such efforts, in 2005 the MBL opened a new $80 million facility for monoclonal antibody production. Its state of the art filling suite allows MBL to continue to fill its own products as well as offer this limited resource for both private and public needs. Currently, as MassBiologics, MBL continues to market it's FDA licenced Td (tetanus and diphtheria) vaccine, providing a substantial proportion of the total US requirements for this key vaccine. In addition, recent years have seen MBL develop expertise and capability in the discovery, production and clinical testing of monoclonal antibodies, including antibodies to Clostridium difficile.

Public service

UMMS is extending its mission of public service through its innovative Commonwealth Medicine initiative. Commonwealth Medicine provides partnership opportunities for dozens of state and local agencies to increase the value and quality of publicly funded health expenditures and to improve access and delivery of care to at-risk and uninsured populations. Through Commonwealth Medicine, public agencies can leverage the academic, research, management and clinical resources of UMMS to optimize efficiency and effectiveness.

Faculty

UMMS faculty members are internationally recognized authorities on AIDS, cancer, diabetes, infectious diseases, pain control, arteriosclerosis, thyroid function, hypertension, joint replacement, organ transplantation, minimally invasive surgery, arthritis, senility and depression, among other areas. Distinguished faculty members include:

• Craig C. Mello, Nobel Prize winner, Howard Hughes Medical Institute Investigator and the Blais University Chair in Molecular Medicine: Co-discoverer of RNA Interference, recipient of the National Academy of Sciences Award in Molecular Biology, the Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research, the Wiley Prize in the Biomedical Sciences, the Gairdner International Award, the Paul Ehrlich and Ludwig Darmstaedter Prize, the Warren Triennial Prize and the Massry Prize;
• Michael Czech. PhD, Chair of the Program in Molecular Medicine: American Diabetes Association Banting Medal for Scientific Achievement (2000);
• Victor Ambros, PhD, 2008 Lasker prize winner, pioneer of microRNAs (miRNA);
• Phillip Zamore, PhD, Howard Hughes Medical Institute Investigator, leader in the field of RNA Interference mechanism, W. M. Keck Foundation's Distinguished Young Scholars in Medical Research Program, a co-founder of Alnylam Pharmaceuticals, a biotechnology company dedicated to the development of small RNA molecules as therapies for human disease, 2009 recipient of Schering-Plough Institute Award.
• Melissa Moore, PhD, Howard Hughes Medical Institute Investigator, co-director of the UMMS RNA Therapeutics Institute
• Roger Davis, PhD,Howard Hughes Medical Institute Investigator; fellow of the Royal Society; H. Arthur Smith Chair in Cancer Research; featured on Biochemistry & Biology and Molecular Biology & Genetics ISIHighlyCited.com
• Michael Green, MD, PhD, Howard Hughes Medical Institute Investigator; Searle Scholar Award; Presidential Young Investigators Award; McKnight Neuroscience Award; Harvey Lecture in 1993; Fox Chase Distinguished Lecture in Cancer Research in 2010; featured on Biochemistry & Biology and Genetics and Cell Biology ISIHighlyCited.com
• Robert Brown, Jr., MD, DPhil, Chair of Neurology; identified genetic mutations related to familial ALS; expert in neurodegenerative and neuromuscular diseases
• Judith Ockene, PhD, the Barbara Helen Smith Chair in Preventive and Behavioral Medicine; women’s health issues (menopause, hormone replacement therapy), health behaviors (alcohol abuse, smoking) quality of life issues for diverse populations.
• Catarina Kiefe, MD, PhD, Chair of Quantitative health Sciences; senior scientist in health care quality measurement and outcomes research

Teaching Affiliates and Clinical Partners

• Main Article UMass Memorial Health Care

As a complement to its education, research and public service mission, the hospital and clinical components of UMMS are part of UMass Memorial Health Care (UMMHC). UMass Memorial is a $1.2 billion health care delivery system with acute care hospitals, ambulatory clinics and a network of primary care physicians and specialists throughout Central Massachusetts. With approximately 13,000 employees, including 1,500 physicians, UMMHC is the largest health care provider in both Central and Western Massachusetts. Its flagship hospital, UMass Memorial Medical Center, straddles two campuses along Route 9 in Worcester, Massachusetts, and it is designated by the American College of Surgeons as a Level I Trauma Center.

UMMHC maintains four community hospitals in addition to its flagship hospital. The four community hospitals include:

• Clinton Hospital in Clinton, Massachusetts
• HealthAlliance Hospital in Fitchburg and Leominster, Massachusetts
• Marlborough Hospital in Marlborough, Massachusetts
• Wing Memorial Hospital in Palmer, Massachusetts

Campus

University of Massachusetts Medical School; Main building, South side.

Lamar Soutter Library

Named in honor of Lamar Soutter, founding Dean School of Medicine, the Lamar Soutter Library at UMMS contains more than 288,000 volumes and is the state's leading source of biomedical information via inter‑library loan. The only public medical library in the state, it is the Regional Medical Library for New England and one of only eight such regional libraries that comprise the National Library of Medicine.

Aaron Lazare Medical Research Building

Aaron Lazare Medical Research Building

To support the more than 260 investigators working on advancements in the treatment of disease and injury, the Aaron Lazare Medical Research Building, a 360,000-square-foot (33,000 m²), state-of-the-art research facility, opened in October 2001. The ten-story structure, which is named for the chancellor emeritus, expanded upon the Medical School’s existing 600,000 square feet (60,000 m²) in on-campus buildings and 83,000 square feet (7,700 m²) in the adjacent Massachusetts Biotechnology Research Park.

Extended Campus

The UMMS extended campus includes the Brudnick Neuropsychiatric Research Institute, and labs and offices within the Massachusetts Biotechnology Research Park in Worcester; sites in Shrewsbury and Auburn; the Eunice Kennedy Shriver Center in Waltham; and the New England Newborn Screening Program and Massachusetts Biologic Laboratories in Jamaica Plain and Mattapan.

Administration

Campus Chancellors

Lamar Soutter

• Chancellor, February 6, 1974 – April 5, 1975

Roger J. Bulger

• Chancellor, January 29, 1976 - November 30, 1978

H. Maurice Goodman

• Acting Chancellor, November 15, 1978 - June 30, 1979

Robert E. Tranquada

• Chancellor, July 1, 1979 – August 31, 1986

James E. Dalen

• Acting Chancellor, August 15, 1986 – August 31, 1987

James B. Hanshaw

• Acting Chancellor, September 1, 1987 - October 31, 1987

Leonard Laster

• Chancellor, November 1, 1987 - August 31, 1990

Aaron Lazare

• Chancellor ad interim, September 4, 1990
• Chancellor, May 15, 1991 – March 15, 2007

Michael F. Collins

• Interim Chancellor, July 1, 2007 - September 26, 2008
• Chancellor September 26, 2008 - present

Deans of the School of Medicine

Lamar Soutter

• Dean, February 24, 1964 - April 5, 1975

R. W. Butcher

• Acting Dean, February 21, 1975 – January 28, 1976

Roger J. Bulger

• Dean, January 29, 1976 - November 30, 1978

H. Maurice Goodman

• Acting Dean, November 15, 1978 - June 30, 1979

Robert E. Tranquada

• Dean, July 1, 1979 – June 4, 1986

James B. Hanshaw

• Dean/Provost, June 4, 1986 - September 30, 1989

Aaron Lazare

• Dean ad interim, October 1, 1989
• Dean, July 25, 1990 – March 15, 2007

Terence R. Flotte

• Dean, May 15, 2007–present
• Executive Deputy Chancellor of UMass Medical School, May 15, 2007–present

Deans of the Program in Biomedical Sciences

George E. Wright

• Acting Dean, Fall 1979 – June 1980
• Dean, June 1981 – June 1984

Trudy G. Morrison

• Acting Dean, June 1980 – June 1981

Deans of the Graduate School of Biomedical Sciences

Thomas B. Miller, Jr.

• Dean, June 1984 – June 2002

Anthony Carruthers

• Dean, December 2002 – present

Deans of the Graduate School of Nursing

Kathleen M. Dirschel

• Dean, June 1985

Lillian R. Goodman

• Dean, September 1991 – November 1999

Doreen Harper

• Dean, July 1, 2000 – November 1, 2005

Paulette Seymour

• Interim Dean, November 1, 2005 – September 5, 2006
• Dean, September 5, 2006 – present

See also

• UMass Memorial Health Care

External links

• UMASS Medical School
• Quality Assurance Review Center
• National Cancer Institute
• National Institutes of Health
• Colleges of Worcester Consortium